Two meta-analyses suggested that primary tumours in the right-sided colon showed worse prognoses than those in the left-sided colon and rectum in patients treated with anti-EGFR antibodies (Arnold et al, 2017; Holch et al, 2017). This evidence concerns the gene EGFR and neoplasm.